SEARCH

SEARCH BY CITATION

References

  • 1
    Hughes RA, Cornblath DR. Guillain−Barré syndrome. Lancet 2005; 366: 16531666.
  • 2
    National Institute of Neurological and Communicative Disorders and Stroke definition (NINCDS). Criteria for diagnosis of Guillain−Barré syndrome. Ann Neurol 1978; 3: 565566.
  • 3
    Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain−Barré syndrome. Ann Neurol 1996; 39: 1728.
  • 4
    van Doorn PA, Ruts L, Jaconbs BC. Clinical features, pathogenesis, and treatment of Guillain−Barré syndrome. Lancet Neurol 2008; 7: 939950.
  • 5
    Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain−Barré syndrome: a case−control study. Neurology 1998; 51: 11101115.
  • 6
    Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain−Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984; 119: 841879.
  • 7
    Centers for Disease Control and Prevention (CDC). Guillain−Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine – United States, June−July 2005. MMWR Morb Mortal Wkly Rep 2005; 54:10231025.
  • 8
    Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain−Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case−control study in Europe. BMJ 2011; 343: d3908.
  • 9
    Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain−Barré syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013; 31: 44484458.
  • 10
    Sejvar JJ, Baughman AL, Wise M. Population incidence of Guillain−Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123133.
  • 11
    Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain−Barré syndrome. Ann Neurol 1990; 27: S21S24.
  • 12
    McGrogan A, Madle GC, Seaman HE, deVries CS. The epidemiology of Guillain−Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32: 150163.
  • 13
    Cheng Q, Wang DS, Jiang GX, Han H, Zhang Y, Wang WZ. Distinct pattern of age-specific incidence of Guillain−Barré syndrome in Harbin. China J Neurol 2002; 249: 2532.
  • 14
    Zhang Y, Wang DS, Han H, Li F, Sheng L, Link H. Epidemiological survey of the incidence of Guillain−Barré syndrome in Harbin from 1997 to 1999. Chin J Clin Rehab 2004; 8: 78127815.
  • 15
    Hui AC, Chow KM, Tang AS, Fu M, Kay R, Wong KS. Electrophysiological, clinical and epidemiological study of Guillain−Barré syndrome in Hong Kong Chinese. J Clin Neurosci 2005; 12: 134136.
  • 16
    Hong X, Zhang Z, Wang J, et al. Epidemiological characteristics of Guillain−Barré syndrome in urban and rural areas in Beijing and Hebei, China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2000; 22: 115119.
  • 17
    Yujie M, Shirui G, Bin Y, et al. Baseline survey of Guillain−Barré syndrome and acute disseminated encephalomyelitis incidence in Heilongjiang Province. Chinese J Pub Health Managem 2012; 6: 783784.
  • 18
    Jiang GX, Cheng Q, Link H, de Pedro-Cues-ta J. Epidemiological features of Guillain−Barré syndrome in Sweden 1978–1993. J Neurol Neurosurg Psychiatry 1997; 62: 447453.
  • 19
    Cuadrado JI, Pedro-Cuesta J, Ara JR, et al. Guillain−Barré syndrome in Spain, 1985–1997: epidemiological and public health views. Eur Neurol 2001; 46: 8391.
  • 20
    Rantala H, Uhari M, Niemela M. Occurrence, clinical manifestation and prognosis of Guillain−Barré syndrome. Arch Dis Child 1991; 66: 706708.
  • 21
    Pier DB, Hallbergson A, Peters JM. Guillain−Barré syndrome in a child with pain: lessons learned from a late diagnosis. Acta Paediatr 2010; 99: 15891591.
  • 22
    van der Maas NA, Kramer MA, Jacobs BC, et al. Guillain−Barré syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst 2011; 16: 243249.
  • 23
    Nobile-Orazio E. Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1996; 60: 599603.
  • 24
    Govoni V, Granieri E, Manconi M, Capone J, Casetta I. Is there a decrease in Guillain−Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurolog Sci 2003; 216: 99103.
  • 25
    Paolino Z, Govoni V, Tola MR, Casetta I, Granieri E. Incidence of the Guillain−Barré syndrome in Ferrara, Northern Italy, 1981–1987. Neuroepidemiology 1991; 10: 105111.
  • 26
    Yan S, Yulin G, Fayi B. The long-term epidemiological trend of Guillain−Barré syndrome and the trend comparison with Europe and America in Shijiazhuang. Chin J Epidemiol 1995; 16: 358.
  • 27
    Lehai Z, Zhijian G, Jie W. Clinical and neurological analysis of Guillain−Barré syndrome below the age of 15 in Dezhou. South China J Prev Med 2006; 32: 5152.
  • 28
    Govoni V, Granieri E. Epidemiology of the Guillain−Barré syndrome. Curr Opin Neurol 2001; 14: 605613.
  • 29
    Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain−Barré syndrome. J Infect Dis 1997; 176(suppl 2): S92S98.